|
On The Fly
| ShowHide Related Items >><< - 11/05/21
- SPI Energy to relocate headquarters to Santa Clara
- 09/07/21
- SPI Energy launches Amazon Store for its expanding Solar4America portfolio
- 02/17/22
- Meihua International Medical Tech Co Ltd trading resumes
- 02/17/22
- Meihua International Medical Tech Co Ltd trading halted, volatility trading pause
- 02/14/22
- Knightscope announces strategic partnership with Allied Universal
- 01/31/22
- KSCP Stock trading resumes
- 01/31/22
- KSCP Stock trading halted, volatility trading pause
- 01/28/22
- KSCP Stock trading resumes
- 02/17/22
- EU passenger car registrations down 6.0% in January
- 02/14/22
- Mullen Automotive announces results from EV market study
- 02/13/22
- Fly Intel: Top five weekend stock stories
- 02/09/22
- Siemens collaborates with Ford on F-150 Lightning charger
- 02/14/22
- Paulson buys Cerner, exits Pretium in Q4
- 02/14/22
- Icahn boosts Xerox, cuts Delek in Q4
- 01/20/22
- Bausch Health: Dr. Yehia Hashad to join Bausch + Lomb as Chief Medical Officer
- 12/06/21
- Bausch Health receives AMPA seal of approval
- 02/03/22 Benchmark
- Benchmark starts 'attractive' FGI Industries at Speculative Buy
- 02/02/22 Benchmark
- FGI Industries initiated with a Speculative Buy at Benchmark
- 02/01/22 RBC Capital
- Bausch Health price target lowered to $34 from $40 at RBC Capital
- 11/03/21 JPMorgan
- Bausch Health earnings selloff a buying opportunity, says JPMorgan
- 09/21/21 JPMorgan
- Bausch has 50% upside based on sum-of-the-parts, says JPMorgan
- 08/04/21 JPMorgan
- Bausch Health selloff on Solta IPO plans overdone, says JPMorgan
- 09/27/21 Maxim
- Maxim starts SPI Energy at Buy on contribution from EV initiatives
- 09/27/21 Maxim
- SPI Energy initiated with a Buy at Maxim
- 02/04/22 Wells Fargo
- Ford separation of BEV, ICE businesses could be catalyst, says Wells Fargo
- 02/04/22 Morgan Stanley
- Tesla sales could top GM plus Ford by 2027, says Morgan Stanley
- 02/04/22 Deutsche Bank
- Ford price target lowered to $21 from $24 at Deutsche Bank
- 01/26/22 JPMorgan
- Ford price target raised to $23 from $20 at JPMorgan
- 02/03/22
- Ford reports Q4 adjusted EPS 26c, consensus 45c
- 02/03/22
- Notable companies reporting after market close
- 10/27/21
- Ford raises FY21 adjusted EBIT view to $10.5B-$11.5B from $9B-$10B
- 10/27/21
- Ford reports Q3 adjusted EPS 51c, consensus 27c
- 11/02/21
- Bausch Health backs FY21 revenue view $8.4B-$8.6B, consensus $8.51B
- 11/02/21
- Bausch Health reports Q3 GAAP EPS 52c, consensus $1.29
|
|
On The Fly
| ShowHide Related Items >><< VRTX Vertex Pharmaceuticals - 01/26/22
- Vertex Pharmaceuticals sees FY22 product revenue $8.4B-$8.6B, consensus $8.22B
- 01/11/22
- Vertex Pharmaceuticals receives EC approval for Kaftrio label extension
- 01/09/22
- Fly Intel: Top five weekend stock stories
- 12/01/21
- Vertex Pharmaceuticals announces data from VX-147 study
SWK Stanley Black & Decker - 02/01/22
- Stanley Black & Decker to begin $4B share repurchase program in Q1
- 01/26/22
- Stanley Black & Decker to restate previously issued financial statements
- 12/08/21
- Stanley Black & Decker to sell most security assets to Securitas for $3.2B
- 09/13/21
- Stanley Black & Decker to acquire Excel Industries for $375M, sees accretion
- 12/22/21
- Sight Sciences receives FDA 510(k) clearance of TearCare System
- 11/17/21
- Sight Sciences announces publication of data on MGS using OMNI Surgical System
- 11/10/21
- Sight Sciences reports FDA authorization for PRECISION trial in POAG
- 10/20/21
- Sight Sciences announces TearCare clinical data published
- 12/03/21
- SolarEdge jumps 2.6% to $315.10 after being included in S&P500 effective 12/20
- 12/03/21
- Signature Bank, SolarEdge named to join the S&P 500 on December 20
- 12/03/21
- SolarEdge to replace Hanesbrands in S&P500 on 12/20
- 11/26/21
- USITC says tariffs on imported solar equipment continues to be necessary
- 01/28/22
- Insulet announces FDA clearance of Omnipod 5 for ages six and older
- 11/04/21
- Insulet tightens FY21 revenue view higher to up 18%-20% from 16%-20%
- 09/30/21
- Insulet presnts Omnipod 5 trial extension phase results
- 08/16/21
- Insulet gets FDA clearance of Lyumjev for use with Omnipod products in U.S.
- $5,480.00 /
-18.99 (-0.35%) - 11/03/21
- NVR authorizes repurchase of $500M of outstanding common stock
- 08/04/21
- NVR authorizes repurchase of $500M in common stock
- 12/27/21
- Mister Car Wash falls -5.9%
- 12/22/21
- Mister Car Wash falls -7.1%
- 12/08/21
- Mister Car Wash to acquire 33 locations in Florida
- 12/07/21
- Mister Car Wash acquires Downtowner Car Wash in Cape Coral, FL
- 02/03/22
- Constellation Energy to replace Gap in S&P 500 at open on 2/3
- 02/03/22
- Gap to replace Jack in the Box in S&P 400 at open on 2/3
- 01/11/22
- Glaukos' iDose TR shows sustained IOP reduction in Phase 2b study
- 01/11/22
- Glaukos says first patient enrolled in presbyopia phase 2 trial
- 01/11/22
- Glaukos announces first patient enrolled in dry eye disease Phase 2 trial
- 01/06/22
- Glaukos announces FDA 510k clearance of iPRIME
- 01/13/22
- First Solar's thin film PV technology selected by Swift Current
- 01/07/22
- Greenidge Generation names Terence Burke as General Counsel
- 11/22/21
- First Solar announces Lightsource bp, bp sign multi-year orders for modules
FB Ticker changed to META - $243.71 /
-79.34 (-24.56%) - 02/02/22
- Meta Platforms says expects pressure on impression growth in the near term
- 02/02/22
- Meta Platforms extends decline, now down 23% following earnings
- 02/02/22
- Meta Platforms down 18% after earnings and guidance miss
- 02/02/22
- Meta Platforms sees trading on Nasdaq under ticker 'META' in first half of 2022
- 12/16/21
- Exelon says New York State Public Service Commission approves separation
- 12/07/21
- Armada Hoffler to acquire Exelon building in Baltimore's Harbor Point
- 01/10/22
- DexCom CEO: G7 CGM system is about 60% smaller than G6
- 09/29/21
- DexCom's G6 CGM System now covered in Manitoba for Type 1 diabetes
- 09/13/21
- DexCom COO Blackford resigns to pursue other opportunities
- 12/10/21
- C.H. Robinson amends record date for upcoming dividend
- 12/09/21
- C.H. Robinson raises quarterly dividend to 55c per share from 51c
- 10/26/21
- C.H. Robinson CEO says capacity to remain tight
- 10/19/21
- SPS Commerce, C.H. Robinson collaborate on streamlined carrier service
- $102.84 /
-0.345 (-0.33%) - 01/28/22
- Church & Dwight raises dividend 4% to 26.25c
- 12/27/21
- Church & Dwight completes purchase of TheraBreath
- 11/29/21
- Church & Dwight acquires TheraBreath brand for $580M
- 01/13/22
- ReShape Lifesciences appoints Michael Bordainick as SVP, Commercial Operations
- 11/08/21
- Alcon to acquire Ivantis for $475M upfront
- 08/18/21
- Alcon rises 12.1%
- 08/18/21
- Alcon rises 11.4%
- 02/03/22 Needham
- SolarEdge upgraded to Buy at Needham on limited CA NEM impact
- 02/03/22 Needham
- SolarEdge upgraded to Buy from Hold at Needham
- 01/31/22 Goldman Sachs
- SolarEdge price target lowered to $404 from $448 at Goldman Sachs
- 01/28/22 Citi
- SolarEdge price target lowered to $310 from $385 at Citi
- 02/03/22 BTIG
- Insulet upgraded to Buy from Neutral at BTIG
- 01/31/22 Oppenheimer
- Insulet upgraded to Outperform from Perform at Oppenheimer
- 01/28/22 Stifel
- Stifel senses 'meaningful patient demand' for Insulet's Omnipod 5
- 01/28/22 Piper Sandler
- Insulet approval 'clear positive' after several delays, says Piper Sandler
- 02/03/22 BTIG
- DexCom upgraded to Buy from Neutral at BTIG
- 01/25/22 Piper Sandler
- DexCom shared continue to offer great entry point, says Piper Sandler
- 01/19/22 Wells Fargo
- Wells Fargo upgrades DexCom to Overweight with $575 price target
- 02/03/22 KeyBanc
- C.H. Robinson price target lowered to $125 from $135 at KeyBanc
- 02/03/22 UBS
- C.H. Robinson downgraded to Neutral from Buy at UBS
- 02/03/22 Citi
- C.H. Robinson price target lowered to $108 from $125 at Citi
- 02/03/22 Stifel
- C.H. Robinson upgraded to Buy from Hold at Stifel
- $5,480.00 /
-18.99 (-0.35%) - 02/03/22 UBS
- NVR upgraded to Neutral from Sell at UBS
- 01/19/22 UBS
- NVR initiated with a Sell at UBS
- 10/14/21 JPMorgan
- NVR price target lowered to $5,770 from $6,300 at JPMorgan
- 04/15/21 Wells Fargo
- NVR initiated with an Equal Weight at Wells Fargo
- 02/03/22 William Blair
- Glaukos upgraded to Outperform from Market Perform at William Blair
- 01/19/22 Wells Fargo
- Wells Fargo upgrades Glaukos to Equal Weight, raises price target to $56
- 01/19/22 Wells Fargo
- Glaukos upgraded to Equal Weight from Underweight at Wells Fargo
- 01/18/22 BTIG
- Glaukos upgraded to Buy from Neutral at BTIG
- 01/18/22 Stephens
- Alcon downgraded to Equal Weight from Overweight at Stephens
- 01/07/22 Morgan Stanley
- Alcon downgraded to Equal Weight at Morgan Stanley on relative valuation
- 01/07/22 Morgan Stanley
- Alcon downgraded to Equal Weight from Overweight at Morgan Stanley
- 11/11/21 JPMorgan
- Alcon price target raised to CHF 72.20 from CHF 69.80 at JPMorgan
FB Ticker changed to META - $243.71 /
-79.34 (-24.56%) - 02/03/22 RBC Capital
- Meta Platforms price target lowered to $315 from $400 at RBC Capital
- 02/03/22 Bernstein
- Meta Platforms price target lowered to $350 from $400 at Bernstein
- 02/03/22 BofA
- Meta Platforms price target lowered to $333 from $410 at BofA
- 02/03/22 Jefferies
- Meta Platforms price target lowered to $350 from $420 at Jefferies
- 02/03/22 Barclays
- Gap downgraded to Equal Weight from Overweight at Barclays
- 01/18/22 Morgan Stanley
- Gap downgraded to Underweight from Equal Weight at Morgan Stanley
- 01/04/22 JPMorgan
- Gap price target lowered to $18 from $22 at JPMorgan
- 11/30/21 Jefferies
- Gap assumed with a Hold at Jefferies
- $102.84 /
-0.345 (-0.33%) - 02/03/22 Argus
- Church & Dwight cut to Hold at Argus on margin pressure, valuation
- 02/03/22 Argus
- Church & Dwight downgraded to Hold from Buy at Argus
- 01/31/22 Truist
- Church & Dwight price target raised to $120 from $100 at Truist
- 01/31/22 Jefferies
- Church & Dwight target raised to $118 at Jefferies after 'upbeat' analyst day
VRTX Vertex Pharmaceuticals - 02/03/22 RBC Capital
- Vertex Pharmaceuticals cut to Sector Perform at RBC Capital on valuation
- 02/03/22 RBC Capital
- Vertex downgraded to Sector Perform from Outperform at RBC Capital
- 01/27/22 Jefferies
- Vertex Pharmaceuticals 'best large cap biotech in this market,' says Jefferies
- 01/20/22 BMO Capital
- Vertex upgraded to Outperform from Market Perform at BMO Capital
- 02/03/22 RBC Capital
- Exelon cut to Sector Perform at RBC Capital on ROE underperformance at ComEd
- 02/03/22 Edward Jones
- Constellation Energy initiated with a Sell at Edward Jones
- 02/03/22 Guggenheim
- Constellation Energy initiated with a Neutral at Guggenheim
- 02/03/22 Wells Fargo
- Wells Fargo downgrades Exelon to Equal Weight, lowers price target to $45
- 02/03/22 Mizuho
- Exelon price target lowered to $43 from $57 at Mizuho
- 02/03/22 Wells Fargo
- Wells Fargo bullish on Constellation Energy, initiates with an Overweight
SWK Stanley Black & Decker - 02/03/22 Citi
- Stanley Black & Decker resumed with a Buy at Citi
- 02/02/22 Wells Fargo
- Stanley Black & Decker price target lowered to $209 from $219 at Wells Fargo
- 01/04/22 Barclays
- Stanley Black & Decker price target raised to $232 from $231 at Barclays
- 12/16/21 Mizuho
- Stanley Black & Decker initiated with a Buy at Mizuho
- 02/02/22 Stifel
- Mister Car Wash initiated with a Hold at Stifel
- 01/18/22 Morgan Stanley
- Mister Car Wash upgraded to Overweight from Equal Weight at Morgan Stanley
- 10/13/21 Seaport Global
- Valvoline upgraded to Buy from Neutral at Seaport Global
- 09/17/21
- Fly Intel: Top five analyst upgrades
- 02/03/22 William Blair
- William Blair starts Sight Sciences at Outperform on 'massive opportunity'
- 02/03/22 William Blair
- Sight Sciences initiated with an Outperform at William Blair
- 01/14/22 Piper Sandler
- Piper tells small cap investors to buy basket of recent med tech IPOs
- 01/10/22 Piper Sandler
- Piper recommends buying Sight Sciences after Q4 beat
- 02/03/22 Benchmark
- Benchmark starts 'attractive' FGI Industries at Speculative Buy
- 02/02/22 Benchmark
- FGI Industries initiated with a Speculative Buy at Benchmark
- 02/03/22 BofA
- BofA cuts First Solar to Neutral, sees 'less clear' future on tariff headwinds
- 02/03/22 BofA
- First Solar downgraded to Neutral from Buy at BofA
- 01/31/22 Goldman Sachs
- First Solar price target lowered to $67 from $74 at Goldman Sachs
- 01/28/22 Citi
- First Solar price target lowered to $80 from $100 at Citi
VRTX Vertex Pharmaceuticals - 01/26/22
- Vertex Pharmaceuticals reports Q4 EPS $3.37, consensus $3.29
- 01/26/22
- Notable companies reporting after market close
- 11/02/21
- Vertex Pharmaceuticals raises FY21 product revenue view to $7.4B-$7.5B
- 11/02/21
- Vertex Pharmaceuticals reports Q3 EPS $3.28, consensus $3.08
SWK Stanley Black & Decker - 02/01/22
- Stanley Black & Decker sees FY22 adjusted EPS $12.00-$12.50, consensus $11.94
- 02/01/22
- Stanley Black & Decker reports Q4 EPS $2.14, consensus $2.04
- 01/31/22
- Notable companies reporting before tomorrow's open
- 01/10/22
- Sight Sciences sees FY21 revenue $48.8M-$49.1M, consensus $47.93M
- 01/10/22
- Sight Sciences reports preliminary Q4 revenue $14.5M-$14.8M, one estimate $13.7M
- 11/10/21
- Sight Sciences sees FY21 revenue $47.5M-$48.5M, consensus $46.64M
- 11/10/21
- Sight Sciences reports Q3 EPS (43c), three estimates (37c)
- 11/02/21
- SolarEdge sees Q4 revenue $530M-$560M, consensus $553.33M
- 11/02/21
- SolarEdge reports Q3 adjusted EPS $1.45, consensus $1.36
- 11/04/21
- Insulet reports Q3 EPS 18c, consensus 24c
- 08/05/21
- Insulet backs FY21 revenue growth view 16%-20%, consensus $1.08B
- 08/05/21
- Insulet sees Q3 revenue growth 11%-18%, consensus $274.16M
- 08/05/21
- Insulet reports Q2 EPS (37c), consensus 13c
- $5,480.00 /
-18.99 (-0.35%) - 02/01/22
- NVR reports Q4 EPS $89.09, consensus $99.76
- 10/21/21
- NVR reports Q3 EPS $86.44, consensus $92.51
- 11/11/21
- Mister Car Wash narrows FY21 adjusted EPS view to 40c-44c from 39c-44c
- 11/11/21
- Mister Car Wash reports Q3 adjusted EPS 11c, consensus 10c
- 08/12/21
- Mister Car Wash sees FY21 EPS 39c-44c
- 08/12/21
- Mister Car Wash reports Q2 adjusted EPS 14c vs. 0c last year
- 11/23/21
- Gap reports Q3 Old Navy SSS down 9% y/y
- 11/23/21
- Gap cuts FY21 adjusted EPS view to $1.25-$1.40 from $2.10-$2.25
- 11/23/21
- Gap reports Q3 adjusted EPS 27c, consensus 50c
- 11/23/21
- Notable companies reporting after market close
- 11/04/21
- Glaukos sees FY21 net sales $285M-$290M, consensus $287.86M
- 11/04/21
- Glaukos reports Q3 adjusted EPS (21c), consensus (24c)
- 08/05/21
- Glaukos sees FY21 revenue $285M-$290M, consensus $296.24M
- 08/05/21
- Glaukos reports Q2 adjusted EPS (11c), consensus (29c)
- 11/04/21
- First Solar backs FY21 net sales view $2.875B-$3.1B, consensus $2.92B
- 11/04/21
- First Solar backs FY21 EPS view $4.00-$4.60, consensus $4.14
- 11/04/21
- First Solar reports Q3 EPS 42c, consensus 59c
- 11/04/21
- Notable companies reporting after market close
FB Ticker changed to META - $243.71 /
-79.34 (-24.56%) - 02/02/22
- Meta sees Q1 revenue $27B-29B, consensus $30.14B
- 02/02/22
- Meta reports Q4 EPS $3.67, consensus $3.84
- 02/02/22
- Notable companies reporting after market close
- 10/25/21
- Facebook reports Q3 EPS $3.22, consensus $3.19
- 11/03/21
- Exelon narrows FY21 adjusted EPS view to $2.70-$2.90 from $2.60-$3.00
- 11/03/21
- Exelon reports Q3 adjusted EPS $1.09B, consensus $1.09
- 08/04/21
- Exelon backs FY21 adjusted EPS view $2.60-$3.00, consensus $2.75
- 08/04/21
- Exelon reports Q2 adjusted EPS 89c, consensus 60c
- 01/10/22
- DexCom sees Q4 revenue $698M, consensus $696.47M
- 10/28/21
- DexCom sees FY21 revenue $2.425B-$2.45B, consensus $2.4B
- 10/28/21
- DexCom reports Q3 EPS 71c, consensus 63c
- 02/02/22
- C.H. Robinson reports Q4 EPS $1.74, consensus $1.85
- 10/26/21
- C.H. Robinson reports Q3 EPS $1.85, consensus $1.42
- 10/26/21
- Notable companies reporting after market close
- $102.84 /
-0.345 (-0.33%) - 01/28/22
- Church & Dwight sees Q1 EPS 75c, consensus 86c
- 01/28/22
- Church & Dwight sees FY22 EPS $3.14-$3.26, consensus $3.21
- 01/28/22
- Church & Dwight reports Q4 adjusted EPS 60c, consensus 60c
- 01/27/22
- Notable companies reporting before tomorrow's open
- 11/09/21
- Alcon reports Q3 core EPS 54c, consensus 49c
- 08/17/21
- Alcon raises FY21 core EPS view to $2.00-$2.10 from $1.85-$1.95
- 08/17/21
- Alcon reports Q2 core EPS 56c, consensus 45c
|
